Chimeric Antigen Receptor T (CAR-T) Cells Market Expected To Reach $14.35 billion in 2028

Overview and Scope
The chimeric antigen receptor T (CAR-T) cells refers to genetically engineered cells that fight with cancer cells to treat the disease. The chimeric antigen receptor T (CAR-T) cells therapy is a form of treatment in which the patient’s T cells, a particular type of immune system cell, are altered in a lab so they will target cancer cells. Blood from a patient is drawn to get T cells. Then, in the lab, T cells are given the gene for a unique receptor, chimeric antigen receptor T (CAR-T), that attaches to a particular protein on the patient’s cancer cells and helps fight cancer.

Sizing and Forecast
The chimeric antigen receptor t (car-t) cells market size has grown exponentially in recent years. It will grow from $2.76 billion in 2023 to $3.89 billion in 2024 at a compound annual growth rate (CAGR) of 40.9%. . The growth in the historic period can be attributed to breakthrough fda approvals, successful clinical trials and patient outcomes, advances in gene editing techniques, growing investment from pharmaceutical companies, rising incidence of cancer .

The chimeric antigen receptor t (car-t) cells market size is expected to see exponential growth in the next few years. It will grow to $14.35 billion in 2028 at a compound annual growth rate (CAGR) of 38.5%. . The growth in the forecast period can be attributed to regulatory streamlining, the exploration of car-t therapy, market expansion in emerging economies, personalized medicine adoption, awareness and education. Major trends in the forecast period include off-the-shelf car-t therapies, combination therapies, technological advancements, long-term safety and efficacy, advancements in manufacturing.

Order your report now for swift delivery, visit the link:
https://www.thebusinessresearchcompany.com/report/chimeric-antigen-receptor-t-car-t-cells-global-market-report

Segmentation & Regional Insights
The chimeric antigen receptor t (car-t) cells market covered in this report is segmented –
1) By Target Antigen: CD19, CD22, Other Antigens
2) By Application: Acute Lymphoblastic Leukaemia, Diffuse Large B-Cell Lymphoma, Other Applications
3) By End User: Hospitals, Cancer Research Centres, Clinics

North America was the largest region in the chimeric antigen receptor T (CAR-T) cells market in 2023. The regions covered in the chimeric antigen receptor T (CAR-T) cells market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Intrigued to explore the contents? Secure your hands-on a free sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=8124&type=smp

Major Driver Impacting Market Growth
The increasing occurrence of cancer is driving the chimeric antigen receptor T (CAR-T) cells market. Cancer is a chronic disease in which normal body cells divide and grow without any control and affect the nearest body tissue and turn into tumors cells. The chimeric antigen receptor T (CAR-T) cells are used to treat various types of cancers such as hematological malignancies, including acute lymphoblastic leukemia, chronic lymphocytic and can also treat solid tumors such as breast cancer and sarcoma. For instance, in 2021, according to the American Cancer Society, a voluntary health organization, global cancer patients diagnosed is expected to reach 1.9 million in 2021. Due to population increase and age, the worldwide burden of cancer is predicted to reach 27.5 million new cases and 16.2 million cancer deaths by 2040. Therefore, the rising prevalence of cancer disease is anticipated to boost the chimeric antigen receptor T (CAR-T) cells market in the upcoming years.

Key Industry Players
Major companies operating in the chimeric antigen receptor T (CAR-T) cells market report are Novartis International AG, Pfizer Inc, Kite Pharma, Autolus Therapeutics Plc, CARsgen Therapeutics Company Limited, Bristol-Myers Squibb Company, Legend Biotech, Mustang Bio Inc, Bluebird Bio Inc, Legend Biotech, Allogene Therapeutics, Atara Biotherapeutics, Bellicum Pharmaceuticals, Carisma Therapeutics, TCR² Therapeutics.

The chimeric antigen receptor t (car-t) cells market report table of contents includes:

1. Executive Summary

2. Chimeric Antigen Receptor T (CAR-T) Cells Market Characteristics

3. Chimeric Antigen Receptor T (CAR-T) Cells Market Trends And Strategies

4. Chimeric Antigen Receptor T (CAR-T) Cells Market – Macro Economic Scenario

5. Global Chimeric Antigen Receptor T (CAR-T) Cells Market Size and Growth

…..

32. Global Chimeric Antigen Receptor T (CAR-T) Cells Market Competitive Benchmarking

33. Global Chimeric Antigen Receptor T (CAR-T) Cells Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Chimeric Antigen Receptor T (CAR-T) Cells Market

35. Chimeric Antigen Receptor T (CAR-T) Cells Market Future Outlook and Potential Analysis

36. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293

Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model